Select year

2026 2025 2024 2023 2022 Earlier

shown/page

5

2026.07.17

ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor
ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor

2026.07.15

Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma
Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma

2026.06.12

Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem
Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem

2026.05.25

From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released
From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released

2026.05.14

Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access
Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com